Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA
The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.
1.00
Épingles correspondant à tag:Foundayo
Trier par
Filtres Foundayo
Publié depuis Tout
Trier par
Lilly lance la construction d'une usine Foundayo de 6,5 milliards de dollars à Generation Park, Houston
CONFIRMÉCONFIANCE 84 %Le communiqué de Lilly porte la mention "HOUSTON[4], 21 septembre 2026" et indique que Lilly "a posé la première pierre aujourd'hui à Houston, Texas[6]" ; Community Impact[2] rapporte que la cérémonie s'est tenue le 21 septembre.
Une usine de 236 acres qui produira le principe actif de la pilule amaigrissante Foundayo de Lilly, avec plus de 600 emplois permanents et environ 4 000 emplois de chantier. Lilly la prévoit opérationnelle d'ici 2030.
$6.5B
1.00
Aujourd’hui
National Checkers DayEli Lilly Q3 2026 Earnings Call
ESTIMÉCONFIANCE 71 %Lilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com[2] and Nasdaq[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.
1.00